Complete financial analysis of Evelo Biosciences, Inc. (EVLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evelo Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fury Gold Mines Limited (FURY) Income Statement Analysis – Financial Results
- Guotai Junan Securities Co., Ltd. (GUOSF) Income Statement Analysis – Financial Results
- Sekisui House, Ltd. (1928.T) Income Statement Analysis – Financial Results
- Sterling Metals Corp. (SAGGF) Income Statement Analysis – Financial Results
- Kingdom Holding Company (4280.SR) Income Statement Analysis – Financial Results
Evelo Biosciences, Inc. (EVLO)
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.55M | 83.64M | 69.62M | 63.13M | 39.89M | 19.96M | 9.13M |
| General & Administrative | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Other Expenses | 0.00 | 486.00K | -1.37M | 1.08M | 1.16M | -301.00K | -20.00K |
| Operating Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Cost & Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Interest Income | 4.67K | 3.61K | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.67M | 3.61M | 2.11M | 1.05M | 1.56M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.06M | 2.22M | 2.03M | 1.76K | 1.94K | 834.00 | 495.00 |
| EBITDA | -106.35M | -115.40M | -91.89M | -86.36M | -58.10M | -26.70M | -12.53M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -108.47M | -115.40M | -91.89M | -86.36M | -58.10M | -27.53M | -13.03M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.13M | -6.35M | -1.37M | 885.00K | 1.16M | -516.00K | -307.00K |
| Income Before Tax | -113.60M | -121.75M | -93.26M | -85.47M | -56.95M | -28.05M | -13.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 930.00K | 428.00K | 409.00K | 190.00K | -3.09M | 215.00K | 287.00K |
| Net Income | -114.53M | -122.18M | -93.67M | -85.66M | -53.85M | -28.05M | -13.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| Weighted Avg Shares Out | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.00K | 141.00K |
| Weighted Avg Shares Out (Dil) | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.54K | 141.74K |
EVLO to Provide Dominion Energy With Safety Enhanced Energy Storage Systems
MONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achievement in its relationship with investor-owned utility Dominion Energy (Dominion) to develop a battery energy storage...
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Evelo Biosciences shares tank 46% after trial failure
Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding miss, the treatment failed to outperform the placebo, which has no...
Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The study's primary endpoint, the difference in the proportion...
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical...
Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO's platform in atopic dermatitis is concerning. However,...
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Horizon Technology Finance Corporation
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduce s secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into...
Source: https://incomestatements.info
Category: Stock Reports